NTLA

Intellia Therapeutics, Inc.

SEC CIK 1652130
$12.35 −5.4% · 90 days
90-day buys
$0
0 open-market
90-day sells
$0
0 open-market
Net insider flow
+$0
Net buying
Filings shown
31
Most recent
Advertisement

At a glance

Insiders at NTLA have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.

Largest recent trade: Cohen Fred E, NTLA's Director, spent $1.4M of their own money on 150,000 shares at $9, growing their stake 261%.

Most active filer: Leonard John M, with 7 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for NTLA, newest first
View on SEC EDGAR ↗
Advertisement
NTLA
Sell BASTA JAMES · EVP, General Counsel · Open-market sale · filed Mar 3, 2026 ΔOwn −0.8%

Basta James sold $16.7K of NTLA, trimming their stake 1%.

−$16.7K
1,211 sh @ $14
NTLA
Sell Clark Eliana · EVP, Chief Technical Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −0.6%

Clark Eliana sold $8.4K of NTLA, trimming their stake 1%.

−$8.4K
607 sh @ $14
NTLA
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Jan 7, 2026 ΔOwn −3.3%

Leonard John M sold $314.5K of NTLA, trimming their stake 3%.

−$314.5K
34,146 sh @ $9
NTLA
Sell Schultes Birgit C · EVP, Chief Scientific Officer · Open-market sale · filed Jan 7, 2026 ΔOwn −7.9%

Schultes Birgit C sold $78.4K of NTLA, trimming their stake 8%.

−$78.4K
8,508 sh @ $9
NTLA
Sell BASTA JAMES · EVP, General Counsel · Open-market sale · filed Jan 7, 2026 ΔOwn −9.3%

Basta James sold $95.8K of NTLA, trimming their stake 9%.

−$95.8K
10,397 sh @ $9
NTLA
Buy Cohen Fred E · Director · Open-market purchase · filed Jan 7, 2026 ΔOwn +261%

Cohen Fred E, NTLA's Director, spent $1.4M of their own money on 150,000 shares at $9, growing their stake 261%.

+$1.4M
150,000 sh @ $9
NTLA
Sell Lebwohl David · EVP, Chief Medical Officer · Open-market sale · filed Jan 7, 2026 ΔOwn −8.9%

Lebwohl David sold $109.6K of NTLA, trimming their stake 9%.

−$109.6K
11,903 sh @ $9
NTLA
Sell Clark Eliana · EVP, Chief Technical Officer · Open-market sale · filed Jan 7, 2026 ΔOwn −9.8%

Clark Eliana sold $87.6K of NTLA, trimming their stake 10%.

−$87.6K
9,515 sh @ $9
NTLA
Sell Dulac Edward J III · EVP, Chief Financial Officer · Open-market sale · filed Jan 7, 2026 ΔOwn −6.0%

Dulac Edward J Iii sold $58.8K of NTLA, trimming their stake 6%.

−$58.8K
6,379 sh @ $9
NTLA
Sell Dube Michael P · VP, Chief Accounting Officer · Open-market sale · filed Jan 7, 2026 ΔOwn −5.4%

Dube Michael P sold $27.5K of NTLA, trimming their stake 5%.

−$27.5K
2,989 sh @ $9
NTLA
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Dec 12, 2025 ΔOwn −4.4%

Leonard John M sold $474.1K of NTLA, trimming their stake 4%.

−$474.1K
49,959 sh @ $9
NTLA
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Dec 12, 2025 ΔOwn −3.0%

Leonard John M sold $310.9K of NTLA, trimming their stake 3%.

−$310.9K
32,832 sh @ $9
NTLA
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Dec 12, 2025 ΔOwn −0.5%

Leonard John M sold $51.4K of NTLA, trimming their stake 1%.

−$51.4K
5,355 sh @ $10
Advertisement

About NTLA insider activity

This page tracks every recent Form 4 filed for Intellia Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is NTLA insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Intellia Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.